CT9.F CARDIOL THERAPEUTICS CL.A

Healthcare Pharmaceuticals Frankfurt Exchange
0.8900 EUR
Close of Nov 11, 2026
0.7320 1.95
Market cap
EUR 108M
P/E
-
P/B
7.69x
ROE
-140.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is CT9.F undervalued?

Graham number

The Graham number of CARDIOL THERAPEUTICS CL.A cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CARDIOL THERAPEUTICS CL.A fundamental analysis

No fundamental analysis for CARDIOL THERAPEUTICS CL.A yet.

CARDIOL THERAPEUTICS CL.A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CARDIOL THERAPEUTICS CL.A

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38,…

Full company profile